SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected sham in the GALE long-term extension study Safety profile of SYFOVRE in GALE was consistent with previously reported clinical dataData presented during an oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting A Media Snippet accompanying this announcement is available by clicking on the image or link below: WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE)

Related Keywords

Australia ,Switzerland ,United Kingdom ,Waltham ,Leicestershire ,United States ,Canada ,American ,Americans ,Meredith Kaya ,Caroline Baumal ,Lissa Pavluk ,American Society Of Retina Specialists ,Lancet Glob Health ,Exchange Commission On ,Linkedin ,Exchange Commission ,Apellis Pharmaceuticals Inc ,Twitter ,Research Group ,Nasdaq ,American Society ,Retina Specialists ,Annual Scientific ,Term Extension ,Geographic Atrophy ,Safety Information ,Vascular Endothelial Growth Factor ,Prescribing Information ,Private Securities Litigation Reform Act ,Apelli Annual Report ,Macular Degeneration ,Apellis Pharmaceuticals ,Nc ,Syfovre ,Injection ,The Gale ,Derby ,Pegcetacoplan ,Sale ,